

**NEWS RELEASE**

**Titanium-Nitride-Oxide Bio Active Technology in ACS Patients:  
Present and Future**

**EuroPCR Symposium, Wednesday, 18<sup>th</sup> May 2011, 12:00-13:30, Room Maillot  
Chairpersons: J.Fajadet, M.Sabaté**

The learning objectives of this key Scientific Symposium held during the EuroPCR 2011 congress were to review why Acute Coronary Syndrome patients are still a challenging indication for PCI, to understand the Titanium-Nitride-Oxide coated stents potential interest for ACS patients and to describe the latest TITAN2 bio-active stent clinical data and finally to share the next coming applications of this technology.

First, Dr Manel Sabaté, Hospital Clinic, Barcelona, Spain, introduced the symposium with a lecture explaining how the thrombogenic and inflammation context of ACS patients should lead interventionists to a rationale stent choice. Indeed, delayed healing, late incomplete stent apposition and hypersensitivity reaction are pathological surrogates of the first generation DES thrombosis in ACS patients.

Then, Dr Pasi Karjalainen, Satakunta Heart Center, Pori, Finland, presented the latest results from the international prospective multicenter randomized trial BASE-ACS comparing outcomes of 827 patients treated either with the Bio Active Stent coated with Titanium-Nitride-Oxide (Titan2) or with the market leading Drug Eluting Stent coated with Everolimus (XienceV). The results presented as well during the late breaking trials at EuroPCR 2011 did confirm the non-inferiority of the Bio Active stent at 12 months with MACE rates of 9.6% versus 9.0% respectively for Titan2 and XienceV ( $p=0.81$ ).

Dr Michaël Angioi, University Hospital Nancy, France, gave a lecture about the results of the large scale prospective registry CATS-AMI with 2137 AMI patients treated with the Titan2 Bio Active Stent and showing a low MACE rate of 9.8% at 12 months.

Dr Tuomas Kiviniemi, Satakunta Heart Center, Pori, Finland, presented the optical coherence tomography (OCT) randomized sub-study of the BASE-ACS trial which has shown that the binary strut coverage was significantly favoring Titan2 Bio Active Stent with 99.4% strut coverage versus 89.2% for the XienceV ( $p<0.001$ ), results that were correlated to a reduction of the coronary flow reserve (CFR) indicating that the coronary microcirculation was decreased at 9 months in the XienceV group versus the Titan2 group.

Finally, Dr Jean Fajadet, Clinique Pasteur, Toulouse, France, introduced the future developments of the next generation of Bio Active Stent called OPTIMAX and the future new generation of Bio Active Eluting stents called the VINCI disclosing for the first time the spectacular Hexacath patented nano-structuration technology.

### **About Titan2 Bio Active Stent**

The Titan2 stent from Hexacath France, is a unique category of coronary stent which is neither a bare metal stent (BMS) nor a drug eluting stent (DES). This stent is coated with a biological active compound called Titanium-Nitride-Oxide. The mechanism of action of this compound while being less aggressive is similar to that found with several of the drugs used with (DES) whilst not carrying the side effects inherent to such drugs. The bio-active coating has shown to inhibit platelet aggregation, fibrin deposition, promote re-endothelialization and minimize inflammation. Bio active stents coated with Titanium-Nitride-Oxide have demonstrated efficacy reducing neointimal proliferation and late loss versus uncoated bare metal stents (BMS) in previous published studies. Unlike drug eluting stents, the Titan2 bio Active stent is free of polymer, cytotoxic or cytostatic drugs which have been associated with impaired re-endothelialization explaining the compulsory need of prolonged dual antiplatelet treatment with current drug eluting stents to avoid late stent unwanted re-occlusion called thrombosis.

### **About Hexacath**

Based in Rueil-Malmaison (Paris area), France, Hexacath is dedicated to the development, manufacture and distribution of innovative cardiovascular products to improve patients treatments. Hexacath has expanded its product portfolio with vascular stents made from nitinol and cobalt chromium platforms coated with its patented biological active coating titanium nitride oxide. During the last 16 years, Hexacath has opened direct subsidiaries in France, Spain, Italy, UK, Belgium, Sweden, Finland, India, China, Brazil, Canada, Hong Kong, and also has a network of distributors in 30 other countries.

**Hexacath, 4, Passage St Antoine, 92508 Rueil-Malmaison, France**

**Tel : 00 33 1 41 39 01 90 – Fax : 00 33 1 41 39 01 93**

**Website :[www.hexacath.com](http://www.hexacath.com)**